Dublin, Dec. 09, 2020 (GLOBE NEWSWIRE) -- The "Antipsychotic Drugs - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
The publisher brings years of research experience to the 8th edition of this report. The 191-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.
Global Antipsychotic Drugs Market to Reach US$21.8 Billion by the Year 2027
Amid the COVID-19 crisis, the global market for Antipsychotic Drugs estimated at US$16.5 Billion in the year 2020, is projected to reach a revised size of US$21.8 Billion by 2027, growing at a CAGR of 4.1% over the analysis period 2020-2027.
Schizophrenia, one of the segments analyzed in the report, is projected to grow at a 4.2% CAGR to reach US$1.1 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Bipolar Disorder segment is readjusted to a revised 4.5% CAGR for the next 7-year period. This segment currently accounts for a 16.1% share of the global Antipsychotic Drugs market.
The U.S. Accounts for Over 28.8% of Global Market Size in 2020, While China is Forecast to Grow at a 6.8% CAGR for the Period of 2020-2027
The Antipsychotic Drugs market in the U.S. is estimated at US$4.7 Billion in the year 2020. The country currently accounts for a 28.84% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$3.8 Billion in the year 2027 trailing a CAGR of 6.8% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.4% and 3.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR while Rest of European market (as defined in the study) will reach US$3.8 Billion by the year 2027.
Depression Segment Corners a 47.9% Share in 2020
In the global Depression segment, USA, Canada, Japan, China and Europe will drive the 3.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$6 Billion in the year 2020 will reach a projected size of US$7.7 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$2.9 Billion by the year 2027, while Latin America will expand at a 4.2% CAGR through the analysis period.
Competitors identified in this market include, among others:
- AstraZeneca PLC
- Bristol-Myers Squibb Company
- GlaxoSmithKline PLC
- Pfizer, Inc.
Key Topics Covered:
I. INTRODUCTION, METHODOLOGY & REPORT SCOPE
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
- Impact of Covid-19 and a Looming Global Recession
- Global Competitor Market Shares
- Antipsychotic Drugs Competitor Market Share Scenario Worldwide (in %): 2018E
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
IV. COMPETITION
- Total Companies Profiled: 32
For more information about this report visit https://www.researchandmarkets.com/r/9alkm6
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.